NEW YORK, April 22, 2015 /PRNewswire/ -- PharmaCyte Biotech, Inc. (OTCMRKTS: PMCB) is a Biotechnology company that was founded in 1996 in Maryland. The company utilizes a cellulose-based live cell encapsulation technology (Cell in-a-Box) to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes. The company operates independently and through wholly-owned subsidiaries. PharmaCyte Biotech has three operations. The first of these includes the cellulose-based live cell encapsulation technology. The second pertains to the work of its subsidiary, Medical Marijuana Sciences, Inc. (MMS). MMS focuses on ways to exploit the benefits of the live cell encapsulation technology in optimizing the anticancer effectiveness of constituents of Cannabis (cannabinoids) against cancers. The third segment consists of the company's nutraceutical formulations and their associated product names and information technology. This segment has a focus on selling its nutraceutical formulations and associated information technology.
Since February 15th, 2015, PMCB share price has been soaring. The stock hits its new high on April 16th, at $0.22 as it increased by 57.14% ($0.14 on February 15th to $0.22 on April 16th). The stock jumped after a research firm upgraded its position on PMCB.
PMCB has achieved developmental progress over the past year and the launch of a series of clinical trials in 2015 should raise the company's profile. These milestones include mid-stage and preclinical studies for the treatment of pancreatic cancer and its serious and debilitating symptoms, and for diabetes.
An analyst brief which covers a brief analysis and analyst recommendation can be viewed in it's entirely by using the link below. There is no cost obligation required to view this report.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Stella Nguyen, experienced research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.